An asymptomatic woman (Ms. Williams) was found to have a severe abnormality in the surface-activated intrinsic coagulation, fibrinolytic, and kinin-generating pathways. Assays for known coagulation factors were nromal while Fletcher factor (pre-kallikrein) was 45%, insufficient to account for the observed markedly prolonged partial thromboplastin time. Plasminogen proactivator was present at 20% of normal levels and addition of highly purified plasminogen proactivator containing 10% plasminogen activator partially corrected the coagulation and fibrinolytic abnormalities but not the kinin-generating defect. This effect was due to its plasminogen activator content. In addition, Williams trait plasma failed to convert prekallilrein to lakkilrein or release kinin upon incubation with kaolin. Kininogen antigen was undetectable. When normal plasma was fractionated to identify the factor that corrects all the abnormalities in Williams trait plasma, the Williams factor was identified as a form of kininogen by its behavior on ion exchange chromatography, gel filtration, disc gel electrophoresis, and elution from an anti-low molecular weight kininogen immunoadsorbent. High molecular weight kininogen as well as a subfraction of low molecular weight kininogen, possessed this corrective activity while the bulk of low molecular weight kininogen functioned only as a kallikrein substrate. Kininogen therefore is a critical factor required for the functioning of Hageman factor-dependent coagulation and fibrinolysis and for the activation of prekallikrein. (Fed. Proc. 1975. 34: 859 
INTRODUCTION
ILagemiian factor (Factor XII) is knoNvii to initiate the I)lasma coagulation (1), kinin-forming (2) , and fibrinolytic pathways of human plasma (3, 4) by activating the precursor proteins, plasma thromboplastin antecedent (Factor XI) (PTA) 1 (1) , prekallikrein (Fletcher factor) (5) , and plasminogein proactivator (6) , respectivelv, to their respective active enzymes. Although patients with deficiency of Factor XII (Hageman trait) have no symptoms (7) , in vitro testing of their plasmas reveals profound defects in surface-activated coagulation, kinin formation, and fibrinolysis. In contrast, Factor XI deficiency in man results in a mild bleeding tendency (8) with a defect in the rate of thrombin formation but no abnormalit) in kallikrein or plasmin formation. Individuals lacking prekallikrein (9) resemble those with Factor XII deficiency and display, in addition to the expected absence of kinin formation, a diminished rate of surface-activated coagulation and fibrinolysis (10, 11) . These latter abnormalities are attributed to a feedback requirement in which kallikrein activates Factor XII to an enzvme that can then act upon each substrate (11) (12) (13) .
This report describes an uinusual patient, Ms. Williams, with profound abnormalities of the Hageman factor-dependent pathwavs. who has diminislhed levels of prekallikrein and plasminogen proactivator and undetectable kininogen. High molecular weight kininogen and a subfraction of low molecular weight kininogen are identified as the corrective factors.
METHODS
Bradykinin triacetate (Sandoz Ltd., Basel, Switzerland) was used as the standard for native bradykinin. Hageman factor-deficient plasma and PTA-deficient plasma containing 0.38%o citrate were fresh-frozen plasma of severely deficient patients collected by ourselves or by Sera-Tec Biologicals, New Brunswick, N. J. Fletcher factor-deficient plasma was a gift from Dr. C. Abildgaard (University of California, Davis, Calif.). Anti-human plasma kallikrein was prepared in rabbits and adsorbed with Fletcher factor-deficient plasma as described previously (14) . Sheep antibody to human low molecular weight kininogen was prepared as previously reported (15, 16) . Preparation of plasma proteins. To obtain normal human plasma for use in assays, 9 vol of blood from healthy donors was drawn directly into plastic tubes containing 1 (18) .
Hageman factor prealbumin fragments utilized in fibrinolytic assays and in the bioassay of prekallikrein were purified by chromatography of plasma on QAE Sephadex twice, Sephadex G 100, SP Sephadex, and elution from alkaline disc gels after electrophoresis, as previously reported by Kaplan et al. (19) . After dialysis, the fragments were concentrated and routinely used at 25 ,g/ml. When assessed functionally, 5 ul of Hageman factor fragment generated 100 ng of bradykinin after incubation with 0.2 ml fresh plasma for 2 min at 37°C. There was no detectable contamination with any of the Hageman factor substrates, plasminogen, plasmin, or kininogen.
Hagcan factor suibstrates. Pre-PTA, prekallikrein, and plasminogen proactivator were isolated from the effluent obtained after passage of 500 ml of plasma over a 10 X 100 cm column of QAE Sephadex at pH 8.3 . The proenzyme mixture was concentrated to 100 ml, the pH brought to pH 6.0 with 1 N HCI, and each proenzyme isolated by sequential chromatography once on SP Sephadex, and twice on Sephadex G 150, as described previously (11) .
Plasminogen. Plasminogen was prepared by affinity chromatography by a modification of the procedure of Deutsch and Mertz (20) . 100 (21, 22) . 10 (35) , which has been described in detail (36) . The (14) .
Kininogen was assayed functionally from colunmn fractions by incubation of 0.5 ml of each fraction with 0.1 ml trypsin (1 mg/ml) for 30 min at 37°C, inactivation of trypsin by further incubation with 0.1 ml soybean trypsin inhibitor (1 mg/ml) for 30 min at 37°C, and determination of the bradykinin generated by bioassay. Kininogen was located antigenically by electroimmunodiffusion (counterimmunoelectrophoresis), performed as described by Schreiber et al. (37) . The precipitin lines were graded by inspection on a 0-4+ scale. The ability of highly purified kininogen to generate bradykinin upon incubation with plasma kallikrein was determined by incubation of 100 /Al kininogen (150 ,ug/ml) with 10 IA kallikrein (50 Atg/ml) for 10 min at 37°C and determination of the bradykinin generated.
Bradykinin was routinely determined by bioassay (5), and in selected experiments the results were confirmed by the radioimmunoassay technique described by Talamo et al. (38) .
Assay of Williams factor. Chromatographic fractions were assayed by testing the ability of these fractions to correct the coagulation and fibrinolytic defects of Williams trait plasma. The coagulation assay was performed by adding 50 ,ul of each fraction to 50 Al of Williams trait plasma and performing a PTT at room temperature. To quantitate the ability of concentrates of these column fractions to correct the coagulation defect in WVilliams trait plasma, we used a method similar to that employed to determine Fletcher factor. 100-A1 dilutions of the concentrate were added to 100 Al of Williams trait plasma and a PTT (27) (Fig. 4) , the Williams trait effluent generated 4 Mg plasmin/ml (the center well), while the normal plasma effluent generated 20 Ag plas- (5), to resolve the Hageman factor substrates. Direct assay of this column did not yield a peak that corrected the abnormalities in Williams trait plasma. However, when the column fractions were concentrated, partial correction of both the coagulation and fibrinolvtic defects was obtained with a mixture containing prekallikrein and plasminogen proactivator but not with pre-PTA. This concentrate was then fractionated by gel filtration with Sephadex G 150 and the fractions were assayed for their ability to correct the coagulation and fibrinolytic defects in Williams trait plasma. As shown in Fig. 6 , fractions containing plasminogen proactivator partially corrected each defect. Again, no correction of kaolin-dependent kinin generation was observed. When tubes 105-115, containing the plasminogen proactivator peak, were concentrated and reassaved. about 10% plasminogen activator was present. Incubation of this concentrate with 10 3 M diisopropylfluorophosphate (DFP) for 2 h at 37°C, followed by extensive dialysis, destroyed its ability to correct Williams trait plasma. Thus the residual plasminogen proactivator, unaffected by this treatment, had no activity. However, the 0.35 M NaCl eluate from QAE Sephadex could correct all the abnormalities in Williams trait plasma. When this fraction was concentrated. dialyzed against 0.03 M sodium acetate buffer. pH 5.6, and fractionated on SP-Sephadex equilibrated with the same buffer (Fig. 7) , a small corrective peak appeared in the effluent coincident with a peak of protein, as assessed by OD 280 nm, that contained a considerable quantity of kininogen antigen. After application of a gradient to 0.4 M NaCl, a major peak was obtained that corrected the coagulation and fibrinolvtic defects of Williams trait plasma superimposed upon the 
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FIGuRE 6 Sephadex G 150 gel filtration of the mixture of prekallikrein and plasminogen proactivator derived from the QAE Sephadex effluent (Fig. 5) . Below is shown the ability of these fractions to correct the coagulation and fibrinolytic abnormalities of Williams trait plasma.
elution of a second peak of antigenic kininogen. When tubes 675-900 were concentrated to 20 ml, this fraction also corrected the prekallikrein activating and kininforming defects.
To determine the amount of kininogen necessary to correct the abnormality in prekallikrein activation, the SP concentrate was first assayed for its ability to correct quantitatively the coagulation defect in Williams trait plasma compared to normal plasma. The SP concentrate contained 28% Williams factor. Multiple dilutions of this factor were then prepared and equal volumes of each dilution were added to Williams trait plasma and assayed for kaolin-activated arginine esterase activity. A dose-dependent correction of the abnormality in prekallikrein activation was observed and maximal correction was obtained at 3.5% of normal plasma concentration (Fig. 8) (Fig. 5) . After the effluent was obtained, a linear salt gradient was applied, shown by the conductivity in millisiemens (mS). The column fractions were assayed for kininogen antigen by counterimmunoelectrophoresis and for their ability to correct the coagulation defect in Williams trait plasma.
ability of kaolini to generate bradykinin as determiiined by bioassay.
This concentrate was next fractionated bV gel filtration on a column of Sephadex G 150 calibrated with proteins of known molecular w,veight (6) . As shown in Fig. 9 , corrective peaks were obtained at mol xvt 175,000 anid 80.000, each associated with a peak of kininogen aintigen. Thus it appeared that certain fractions of kininogen, containing a higlh molecular weight form as well as a low molecular weight form, could correct the coagulation and fibrinolvtic abnormalities in Williams trait plasma. Nevertheless the bulk of the plasma kininogen of mol wt 80.000 present in the 0.20 'M fraction from QAE Sephadex (Fig. 6 ) and the effluent fromii SP-Sephadex (Fig. 7) failed to correct these abnorialities.
WVhen highly purified kininogen was prepared as described in the 'Methods section, by DEAE cellulose batclh adsorption, an antikininogen imnmunoadsorbent, chroimiatographv oIn DEAE cellulose, and gel filtration on BioGel A 0.5 m, kininogens could be further resolved by charge and size. Kininogen corresponding to the 0.20 M eluate fromii QAE Sephadex was resolved on DEAF cellulose into three peaks, designated B1-3. The kininogen present in the 0.35 'M NaCl eluate from QAE Sephadex was found as a separate peak on DEAE cellulose designated B4. As shown in Table V , the Bi, B2, and B3 fractions were predominantly kininogens of low molecular u eight, although fraction B3 /8 was 150,000 daltons; these fractions did not correct Williams trait deficiency. The corrective factor was found associated only with the B4 fractions, regardless of their molecular wveight. The most effective fraction, on a weight basis, was B4-y. Removal of all of the bradvkinin from B4-y 1658 Colman, Bagdasarian, Talamo, Scott, Seavey, Guimaraes, Pierce, and Kaplan FIGURE 9 Sephadex G 150 gel filtration of the major peak of corrective activity eluted from SP Sephadex (Fig. 7) . The (46) and Factor V and VIII deficiency (47) . Alternatively, functional absence of an inhibitor might lead to accelerated catabolism of these proteins, as observed with C3b inactivator deficiency (48) . Further studies are required to distinguish these possibilities.
Finally, our results are also relevant to considerations of the number of kininogens that circulate in plasma. Although it is clear from the studies of Spragg and Austen that the majority of plasma kininogen is of low molecular weight (49), this does not appear to be the sole form of native human kininogen. Previous authors have described a human high molecular weight kininogen that possesses different kinetic properties when activated by kallikrein (15, 20, 50, 51) . It is clear from our studies that such a high molecular weight kininogen can be separated from low molecular weight kininogen and this kininogen has a special function in the early steps of the Hageman factor-dependent pathways. The bulk of plasma low molecular weight kininogen is found in our 0.20 MI fraction from QAE Sephadex and in the effluent from SP Sephadex, and possesses little ability to correct Williams trait deficiency, although it is functional as a kallikrein substrate. However, we have also found a low molecular weight kininogen-containing fraction (Fig. 9 ) that corrects Williams trait deficiency, indicating that it contains the same activity associated with the high molecular weight form. When kininogens were isolated by an alternative procedure (Table IV) , only the B4 kininogens, comprising 22% of total kininogen, corrected Williams trait deficiency. Analysis of this fraction by gel filtration indicates that each of the molecular weight subfractions corrects Williams trait plasma. These are the same kininogen fractions found to have the highest affinity for plasma kallikrein and the greatest rate of cleavage by plasma kallikrein, regardless of size (21, 22) . When we previously fractionated 50 ml of Hageman factordeficient plasma to isolate the Williams factor, all of the corrective activity was found at a mol wt of 175,000, although its identity was not known (52) . It is therefore possible that lower molecular weight forms of kininogen that correct Williams trait deficiency are derived from the heavier fraction, while B3-,, a heavier fraction that does not correct Williams trait deficiency, is a dimer of a low molecular weight kininogen. Alternatively, the large volumes of plasma utilized on the present study may have allowed identification of kininogen heterogeneity that was not previously appreciated.
